Posts Tagged ‘biotech’
Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $7.25 Million Initial Public Offering of Greenwich LifeSciences, Inc.
Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $3 Million Public Offering of Common Stock of Cocrystal Pharma, Inc.
Sichenzia Ross Friedman Ference LLP Represents Rodman & Renshaw as Exclusive Placement Agent for a $5 Million Registered Direct Offering
CEL-SCI Corporation
$5,000,000
Registered Direct Offering of Common Stock
Private Placement of Warrants
Represented Rodman & Renshaw, a unit of H.C. Wainwright& Co., LLC, as Exclusive Placement Agent
August 2016
Read MoreSichenzia Ross Friedman Ference LLP Represents Joseph Gunnar and Fordham Financial Management in $7.5 Million Public Offering of Aytu Bioscience, Inc.
Aytu BioScience, Inc. .
$7,500,000
Public Offering
Common Stock and Warrants
Represented Joseph Gunnar and Fordham Financial Management, Inc. as Lead Manager
May 2016
Read MoreSichenzia Ross Ference LLP Congratulates AIT Therapeutics, Inc. on NASDAQ Uplisting
New York, NY – May 9, 2019 – Sichenzia Ross Ference LLP announced today that the firm represented AIT Therapeutics, Inc. (NASDAQ: AITB), in the Company’s uplisting to the NASDAQ Capital Market. The Sichenzia Ross Ference LLP team was led by founding partner Gregory Sichenzia and partner Avital Perlman. The uplisting is effective for trading…
Read MoreSichenzia Ross Ference LLP Congratulates INmune Bio Inc., on Initial Public Offering
New York, NY – April 9, 2019 – Sichenzia Ross Ference LLP announced today that the firm represented INmune Bio Inc. (NASDAQ: INMB), in the Company’s Initial Public Offering and subsequent listing on the NASDAQ Capital Market. The Sichenzia Ross Ference LLP team was led by founding partner Marc Ross and partners David Manno and Thomas…
Read MoreSichenzia Ross Ference LLP Acts as Principal Attorney Liaison for Zelda Therapeutics Ltd on OTCQX Listing
Press Release – New York, NY – September 14, 2018 – Sichenzia Ross Ference LLP announced today that it has sponsored Zelda Therapeutics Ltd (OTCQX: “ZLDAF”), an Australian biotechnology company studying the use of medicinal cannabis to treat a variety of ailments, for the OTCQX. not assigned biotech | srf llp
Read MoreSichenzia Ross Friedman Ference LLP Congratulates Biomerica, Inc. on NASDAQ Uplisting
New York, NY – August 25, 2016 – Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented Biomerica, Inc. (NASDAQ: BMRA), in the Company’s uplisting to the NASDAQ Capital Market. The Sichenzia Ross Friedman Ference LLP team was led by founding Partner Gregory Sichenzia and Associate Jay Yamamoto. The uplisting is effective for…
Read MoreSichenzia Ross Friedman Ference LLP Attorneys To Join Client DelMar Pharmaceuticals, Inc. at Nasdaq Opening Bell Ringing
Press Release – New York, NY – July 14, 2016 – Sichenzia Ross Friedman Ference LLP partners Gregory Sichenzia and David Manno and counsel Jeffrey Cahlon will join representatives of client DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a clinical stage drug development company with a focus on the treatment of cancer, at the Nasdaq MarketSite in Times…
Read MorePartner Greg Sichenzia to Participate in Panel on Uplisting to a National Exchange at the Marcum MicroCap Conference
Press Release – New York, NY – May 19, 2016 – Founding partner Greg Sichenzia will participate in a panel on uplisting to a national exchange at the 2016 Marcum MicroCap Conference in New York City on June 1, 2016 at 9AM. The panel will address what every company needs to know before, during and…
Read More
